anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

221,281-221,340 of 319,975

filter-aware
03
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
04
The slide uses a vertical timeline structure to organize clinical catalysts by asset.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a process-flow diagram to contrast personalized autologous therapy with off-the-shelf bispecific therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a Gantt-style visualization to show the progress of various drug candidates across different clinical phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
08
The slide outlines a partnership structure involving three distinct therapeutic approaches and a financial deal structure.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a timeline framework to demonstrate historical traction and partnership growth.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a list-based comparison to show market potential for specific drug targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a table to show market opportunity (prevalence) and a diagram to illustrate the mechanism of action for two different drug platforms.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
12
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a combination of a biological mechanism diagram, a checklist of target criteria, and histological images to validate the therapeutic target.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a circular process diagram to illustrate the therapy lifecycle, followed by a zoomed-in molecular interaction diagram.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
15
Includes clinical trial screening data for specific cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
16
The slide uses a table to compare patient demographics and clinical characteristics across different cancer types, specifically focusing on the sufficiency of the melanoma cohort for further development.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
17
Slide compares two generations of therapy; includes clinical metrics like cORR and mDOR.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-flow diagram to distinguish between two generations of TCR-T therapies and their respective trial phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
19
The table highlights key clinical metrics including ORR, cORR, mDOR, and mFU for various patient subgroups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
20
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
Data cut-off Sep 30, 2023. N=16 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
22
Data cut-off Sep 30, 2023. Includes extensive footnotes regarding methodology and specific patient cases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
Includes waterfall plot for BOR and spider plot for response over time. Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
The slide uses a matrix structure to define the patient population and market opportunity.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
25
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
26
The slide uses a biological diagram to illustrate the synergy between CD4 and CD8 T cells in inducing tumor cell death.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses two line charts to demonstrate the superior durability of CD4 T cells in a serial killing assay.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
28
Includes specific clinical details on Grade 3/4 events for two patients in the highest dose cohort (DL4b).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
29
Data cut-off Sep 30, 2023. Slide 29.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
30
Includes waterfall plot and spider plot (longitudinal response). Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
31
Includes p-values for statistical significance across four distinct clinical metrics.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
32
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide uses a two-row layout to contrast GEN1 and GEN2 therapies, each with a 'Next Step' callout.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
34
Uses a ridge plot (joyplot) to visualize distribution of PRAME expression across 7 cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
35
The slide uses a chevron-based process flow to represent a phased development roadmap.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
36
The left side uses a funnel diagram to represent the manufacturing process steps.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
37
The table uses a multi-step funnel approach to arrive at the final patient population count.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
38
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
39
The slide uses a four-column layout to summarize the therapeutic profile of the drug candidate.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
40
Includes histological images of tumor/stroma and a longitudinal bioluminescence imaging study in mice.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
41
The slide features a high-quality photograph of a scientist handling cryogenic materials, reinforcing the 'off-the-shelf' (frozen/stored) nature of the product.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
42
The slide outlines a manufacturing process for off-the-shelf cell therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
43
The slide uses a bulleted list to define the therapeutic rationale and two line charts to provide empirical evidence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
44
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
45
The slide uses a structural diagram to explain the three components of the molecule and a process diagram to show the biological interaction.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
46
Includes a schematic diagram of the bispecific molecule on the left.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
48
The chart uses a broken axis to show early time points and late-stage tumor volume divergence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
49
The slide uses a 3x4 grid of line charts to demonstrate the safety profile of the proprietary TCER format.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
50
The slide uses a horizontal arrow-based process flow to categorize programs by development stage (Clinical vs Preclinical).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
51
Includes ISH images, a prevalence table, and a dot plot comparing peptide density.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
52
Includes study design timeline, histology details, and comparative tumor volume charts (group averages vs individual mice).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
53
The slide illustrates the methodology for PK analysis (injection, sampling, quantification) and presents the resulting concentration-time curve.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
54
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
55
The slide uses four dose-response curves to show cytotoxicity against different target copy numbers.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
56
The chart uses a broken x-axis between -29 and 0. The legend indicates four distinct treatment groups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
57
The slide uses a log-linear plot to demonstrate drug clearance over time.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
58
The slide outlines a standard clinical trial progression from overview to dose escalation and expansion.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
59
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
60
The slide uses a visual metaphor of cell-to-cell interaction to illustrate the therapeutic mechanism.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
61
The funnel is represented as a series of concentric circles/segments.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
62
The chart is a dot plot showing quantitative target density (CpC) for two different peptide targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit